---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019285"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:48:38.664750+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q1 2022 revenue $317M, net earnings $0.59/sh, up from $0.43/sh YoY

## Summary
- Total revenue $316.6M (up 56% YoY from $202.7M); net earnings $168.6M ($0.59 basic EPS vs $0.43).
- Royalties from bamlanivimab/bebtelovimab contributed $307M of total revenue.
- Cumulative program starts reached 84 (up 56% YoY); discovery partners grew to 36 from 29.
- Cash, cash equivalents and marketable securities stood at $786.1M.
- R&D expenses rose to $26.4M from $12.4M YoY, driven by platform investment.

## SEC filing metadata
- accession: 0001564590-22-019285
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459022019285/0001564590-22-019285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459022019285/abcl-8k_20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019285
- JSON: https://secwatch.observer/filing/0001564590-22-019285.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.